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1198Objective: Postoperative bleeding is a major cause of morbidity and mortality after complex aortic surgery.
Intraoperative coagulopathy is a well-known culprit in this process. Recombinant activated factor VII is increas-
ingly used for the postoperative management of such bleeding. We report our experience with the intraoperative
use of this agent.
Methods: We performed a propensity-matched analysis on 376 retrospectively identified patients who under-
went aortic root, arch, or ascending aortic replacement surgeries from 1999 to 2010. We matched a total of
58 patients: recombinant activated factor VII–treated group (n ¼ 29) and nonrecombinant activated factor
VII–treated group (n ¼ 29). We compared the matched patients on re-exploration, mortality, bleeding-related
events, use of blood and blood products, length of intensive care unit stay, duration of hospitalization, and throm-
botic complications.
Results: Propensity-matched patients had similar preoperative and intraoperative characteristics. The mean
dose of recombinant activated factor VII group was 23 12 mg/kg.We found significantly lower rates of surgical
re-exploration (P ¼ .004), fewer prolonged intubations (P ¼ .004), less total chest tube output (P ¼ .01), and
fewer units of packed red blood cells (P ¼ .01) and fresh-frozen plasma (P ¼ .04) transfused postoperatively
in the recombinant activated factor VII group. There was no significant difference in mortality (P¼ 1), duration
of intensive care unit stay (P ¼ .44) or hospital stay (P ¼ .32), or thrombotic complications between the groups
(P ¼ .5).
Conclusions: We recommend the intraoperative administration of low-dose recombinant activated factor VII
but limited to the management of persistent, nonsurgical, mediastinal bleeding in aortic surgery. Further
prospective randomized studies and larger cohorts are needed to verify these findings. (J Thorac Cardiovasc
Surg 2012;143:1198-204)Repair of aortic root, ascending aorta, and aortic arch aneu-
rysms is associated with significant postoperative bleeding
that often requires transfusion of large volumes of blood
and blood products.1 This is a well-known risk factor for
postoperative morbidity and has been reported to cause an
8.1-fold increase in mortality rates.2 In patients undergoing
re-exploration for postoperative bleeding after cardiac sur-
gery, it has been demonstrated that only 50% have a grossly
identifiable surgical source of bleeding.3 This identifies
microvascular bleeding caused by coagulopathy as a major
risk factor for postoperative bleeding. Strategies to prevent
coagulopathic bleeding are essential for the successful man-
agement of patients undergoing complex aortic operations.
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Over the last decade, rFVIIa has been increasingly used in
the postoperative management of intractable bleeding
after cardiac and aortic surgery.6 Of note, the precise dose
required to control bleeding without causing thrombotic
complications is controversial.7 Dose recommendations in
the current literature have ranged from 30 to 200 mg/kg,
which can be administered in multiple doses.
Currently, there are a paucity of data regarding the intra-
operative use of rFVIIa as a measure to minimize postoper-
ative bleeding and associated complications.8 We report our
clinical experience with off-label intraoperative use of
low-dose rFVIIa for inadequate hemostasis in patients
undergoing complex aortic repair procedures.MATERIAL AND METHODS
Study Population
Patients were retrospectively identified from our aortic aneurysm
research registry. From 1999 to 2010, 488 patients underwent repair of
the aortic root, ascending aorta, and arch (Table 1). Excluded from the
study were the patients undergoing concomitant coronary artery bypass
grafting, mitral or tricuspid valve surgery, and congenital surgery. We fur-
ther excluded patients who had abnormalities in the preoperative coagula-
tion panel (prothrombin time, partial thromboplastin time, bleeding time,
and platelet count [if<150 k/mL]). The above exclusion criteria narrowed
the pool to 376 patients. In February 2009, we started administeringgery c May 2012
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DHCA ¼ deep hypothermic circulatory arrest
FFP ¼ fresh-frozen plasma
ICU ¼ intensive care unit
POD ¼ postoperative day
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outlined below. We identified 37 such patients. The remaining patients
served as a control pool for the propensity-matched analysis.
Study End Points
The primary end points of our study were major bleeding requiring
surgical re-exploration and postoperative in-hospital death. Secondary
end points were the use of blood and blood products, delayed chest closure,
postoperative tamponade, chest tube output, duration of intensive care unit
(ICU) stay, prolonged intubation (>48 hours), duration of hospitalization,
and any complication that might be related to thrombosis.
Data Collection
Preoperative and intraoperative data are listed in Table 2. The institu-
tional review board approved the use of these data for the purposes of
this study. All patients undergoing aortic surgery after 2009 were informed
in advance that they might receive factor VII.
Surgical Technique
After endotracheal intubation and administration of appropriate anes-
thetic agents, radial arterial, central venous, and Swan–Ganz catheters
were introduced per routine. Median sternotomy was performed followed
by arterial and venous cannulations as outlined below. Standard cardiopul-
monary bypass techniquewas carried out using membrane oxygenators. Of
note, 152 patients (40%) received right axillary cannulation for arterial
access. Venous access was obtained via cannulation of the right atrium
or the femoral vein. Depending on the complexity of the procedure, mod-
erate to deep systemic hypothermia was used. Mean arterial blood pressure
was kept between 50 and 70 mmHg during cardiopulmonary bypass. Myo-
cardial protection was achieved by antegrade and retrograde cold blood
cardioplegia. Heparin was administered to achieve an activated clotting
time more than 480 seconds. This was neutralized with appropriate use
of protamine administered within 10 minutes after the end of cardiopulmo-
nary bypass. All patients received aminocaproic acid (AMICAR; Lederle
Parenterals, Carolina, Puerto Rico) perioperatively. Generally accepted
criteria were used for re-exploring patients with postoperative bleeding.9
Management of Intraoperative Bleeding
Figure 1 summarizes the algorithm we used to treat intraoperative
bleeding. Beginning in February 2009, rFVIIa was added to this regimen
as described below. If bleeding persisted after routine attempts at surgical
hemostasis, coagulation parameters were measured to rule out any existing
correctable measures. If none existed or corrected, rFVIIa was adminis-
tered at 1 to 2 mg/dose (10–30 mg/kg), which was repeated once if bleeding
persisted. If the surgeon was not satisfied with the degree of hemostasis
despite these measures, the chest was left open and packed with continuous
negative pressure suction dressing for delayed closure. The patient was
subsequently transferred to the ICU for observation and brought back to
the operating room within 24 to 72 hours for definitive closure.The Journal of Thoracic and CarStatistical Analysis
Demographic, perioperative, and intraoperative continuous variables
were compared using the unpaired or paired t test for the prematch and
propensity-matched groups, respectively. Accordingly, dichotomous vari-
ables were compared using the Fisher exact or McNemar test.
Because of the absence of preoperative randomization, a propensity-
matched analysis was performed.10 Propensity scores were generated
through a logistic regression procedure using the following risk factors
observed to be significant in the univariate prematch group comparisons
and deemed likely to cause postoperative bleeding: gender, total body sur-
face area, emergency status of the operation, total pump time, redo sternot-
omy, and use of deep hypothermic circulatory arrest (DHCA). Once
generated, propensity scores were addressed as proposed by Austin.11
Matching without the replacement method was used to pick up a match
from the control group. Finally, patients were matched by an identical
5-digit propensity score. If this could not be done, we then proceeded to
a 4-, 3-, 2-, or 1-digit match. Five-digit matches were 11, and 4-3-2-1
matches were 6, 6, 4, and 2, respectively. We were unable to match 8 pa-
tients who had rFVIIa; therefore, we excluded those from further analysis.
Values are expressed as mean standard deviation, median (minimum–
maximum), or percentage. All analyses were performed with SPSS 13.0
software (SPSS Inc, Chicago, Ill).
RESULTS
Total Prematch Group
The mean age was 63 13 years (19–88), and 64% were
male. The mean intraoperative dose of rFVIIa in 37 patients
was 23 14 mg/kg (10–60). Nineteen patients received 1 mg
of rFVIIa (51%), 13 patients (35%) received 2mg of rFVIIa,
4 patients (10%) received 3mg of rFVIIa, and 1 patient (2%)
received 4 mg of rFVIIa before leaving the operating room.
Of note, none of the patients received additional doses of
rFVIIa after leaving the operating room. The patient who
required 4 mg of rFVIIa had had an acute type A dissection
requiring replacement of the aortic root, arch, and ascending
aorta. Furthermore, the patient was anticoagulated with arga-
troban because of a standing diagnosis of heparin-induced
thrombocytopenia with a preoperative platelet count of
155 3 103/mL.
Prematch Comparison
All performed operations are listed in Table 1. The ascend-
ing aorta was involved in 195 patients (51%), the aortic root
was involved in 94 patients (25%), and the aortic arch was
involved in 105 patients (28%). Prematch baseline variables
are shown inTable 2. In the prematch analysis, therewere sig-
nificantly more male patients in the control group (P ¼ .02).
The rFVIIa group had longer total pump time (P¼ .008) and
aortic crossclamp time (P ¼ .006). Redo sternotomy was
performed in 10 patients (27%) in the rFVIIa group and in
39 patients (11%) in the control group (P ¼ .01). Other
preoperative variables were not statistically different.
Postmatch Comparison
The propensity-matched analysis yielded 58 patients
available for analysis. All variables before administration
of rFVIIa were similar between the 2 groups (Table 2).diovascular Surgery c Volume 143, Number 5 1199
TABLE 1. Performed operations (%)
Before match After match
Overall (n ¼ 376) rFVIIa (n ¼ 37) Control (n ¼ 339) Overall (n ¼ 58) rFVIIa (n ¼ 29) Control (n ¼ 29)
Ascending  arch  AV repair 27 (7) 0 27 (7) 0 0 0
Ascending  arch  AV
replacement
82 (21) 1 (2) 81 (23) 1 (2) 1 (3) 0
Ascending aorta replacement 101 (26) 4 (10) 97 (28) 7 (12) 3 (10) 4 (14)
Root repairþascending 26 (6) 1 (2) 25 (7) 3 (5) 1 (3) 2 (7)
Rootþascending 31 (8) 6 (16) 25 (7) 11 (19) 5 (17) 6 (20)
Root repairþascendingþarch 4 (1) 2 (5) 2 (0.5) 4 (7) 2 (7) 2 (7)
Rootþascendingþarch 33 (8) 9 (24) 24 (7) 13 (22) 7 (24) 6 (20)
Ascendingþarch 58 (15) 14 (37) 44 (12) 17 (29) 10 (34) 7 (24)
Isolated arch 14 (3) 0 14 (4) 2 (3) 0 2 (7)
AV, Aortic valve; rFVIIa, recombinant-activated factor.
Perioperative Management Goksedef et al
P
M
P
MThe mean intraoperative dose of rFVIIa was 23  12 mg/
kg (10–55). Fifteen patients received 1mg of rFVIIa (51%),
10 patients (34%) received 2 mg of rFVIIa, and 4 patients
(13%) received 3 mg of rFVIIa before leaving the operating
room. The rFVIIa group received significantly fewer units
of packed red blood cells (PRBCs) (7  2 vs 9  4,
P ¼ .01) and fresh-frozen plasma (FFP) (4  1 vs 6  2,
P ¼ .04) in the postoperative period (Table 3). There was
a tendency for the rFVIIa group to receive fewer units of
single-donor platelets and cryoprecipitate, but these values
did not reach statistical significance (P¼ .097 and P¼ .091,
respectively).
Five patients (17%) underwent surgical re-exploration
for bleeding in the rFVIIa group compared with 14 patients
(48%) in the control group (P ¼ .004). None of the re-
explored patients had a surgical source of bleeding. OneTABLE 2. Preoperative and operative characteristics of overall population
group before and after propensity match
Variable
Before match
Overall rFVIIa Control
(n ¼ 376) (n ¼ 37) (n ¼ 339)
Age (y) 63  13 59  12 63  13
Gender (male,%) 244 (64) 18 (48) 226 (66)
Body surface area (m2) 1.83  0.2 1.81  0.1 1.84  0.2
Hypertension (%) 304 (81) 30 (81) 267 (78)
COPD (%) 87 (23) 10 (27) 77 (22)
euroSCORE (%) 6.3  3.2 6.5  3.1 6.3  3.2
Renal dysfunction (%) 27 (7) 3 (8) 26 (7)
Preoperative EF (%) 66  13 64  16 66  12
Emergency surgery (%) 72 (19) 6 (16) 66 (19)
Acute dissection (%) 57 (15) 5 (13) 52 (15)
Chronic dissection (%) 13 (3) 1 (2) 12 (3)
Redo sternotomy (%) 49 (13) 10 (27) 39 (11)
TPT (min) 196  70 227  65 193  70
ACC time (min) 133  65 165  76 132  64
DHCA (%) 267 (71) 25 (67) 242 (71)
ACC, Aortic crossclamp time; COPD, chronic obstructive pulmonary disease; DHCA, deep
factor VII; TPT, total pump time; euroSCORE, European System for Cardiac Operative R
1200 The Journal of Thoracic and Cardiovascular Surpatient (3%) in the rFVIIa group had postoperative cardiac
tamponade (caused by excessive packing in a patient who
underwent open chest surgery) compared with 4 patients
(13%) in the control group (P ¼ .25) (Table 3). Patients re-
ceiving rFVIIa had lower total chest tube output when com-
pared with the control group (810 376 mL vs 1020 515
mL, P¼ .01, respectively). All patients had adequate hemo-
stasis before chest closure; 7 patients had delayed chest clo-
sure, and mean chest closure time was 1.4  0.7 days (1–3)
after the initial operation. Two patients (6%) in the rFVIIa
group and 5 patients (17%) in the control group had delayed
chest closure (P ¼ .25).
The median ICU stay was 2 days in the rFVIIa group
(range, 1-7) compared with 3 days in the control group
(range, 1-15). The rate of prolonged intubation was signifi-
cantly lower in the rFVIIa group compared with the controland comparison between recombinant activated factor VII and control
After match
P value
Overall rFVIIa Control
P value(n ¼ 58) (n ¼ 29) (n ¼ 29)
.12 60.3  12 60.3  11 60.3  13 .62
.02 29 (50) 14 (48) 15 (51) 1
.3 1.82  0.1 1.81  0.1 1.82  0.1 .98
.46 46 (80) 24 (82) 22 (75) .5
.34 12 (20) 6 (20) 6 (20) 1
.62 6.5  3.1 6.7  3.5 6.3  2.7 .59
.56 5 (8) 2 (6) 3 (10) 1
.74 65  13 65  11 65  14 .94
.41 11 (18) 5 (17) 6 (21) 1
.49 7 (12) 3 (10) 4 (14) 1
.62 1 (1) 0 1 (3) 1
.01 11 (18) 6 (21) 5 (17) 1
.008 212  61 220  64 203  59 .17
.006 135  62 142  73 128  49 .23
.7 45 (77) 22 (75) 23 (79) 1
hypothermic circulatory arrest; EF, ejection fraction; rFVIIa, recombinant activated
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FIGURE 1. Hemostasis management in aortic surgery. ICU, Intensive care unit; INR, international normalized ratio; PTT, prothrombin time; PLT, platelet;
rFVIIa, recombinant activated factor VII.
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the length of ICU stay (P¼ .44) or duration of hospital stay
(P ¼ .32) between the groups (Table 3).
There were 6 thrombotic complications in 6 patients
(10%) (Table 4). In the rFVIIa group, 1 patient had a stroke
and 1 patient had a transient ischemic attack (7%). In the
control group, 2 patients had a stroke, 1 patient had a tran-
sient ischemic attack, and 1 patient had a myocardial infarc-
tion. There was no statistically significant difference in the
number of thrombotic events between the 2 groups (P¼ .5).The Journal of Thoracic and CarOverall 30-day mortality was 4 of 58 patients (6%), with
2 mortalities in each group. In the rFVIIa group, the first
mortality occurred in a patient who had developed
heparin-induced thrombocytopenia in addition to acute
postoperative renal failure and concomitant sepsis after a re-
operation of aortic root, arch, and ascending aortic replace-
ment. This patient died on postoperative day (POD) 17. The
second mortality also occurred in a patient who underwent
a redo aortic root replacement for an infected mechanical
valve. The coronaries were reimplanted using the Cabroldiovascular Surgery c Volume 143, Number 5 1201
TABLE 3. Postoperative blood and blood product use and bleeding-
related complications in matched patients
rFVIIa
(n ¼ 29)
Control
(n ¼ 29)
P
value
Blood and blood product use
PRBC (units) 7  2 9  4 .01
FFP (units) 4  1 6  2 .04
Platelets (single donor) 3  2 4  2 .097
Cryoprecipitate (units) 12  2 14  3 .091
Clinical bleeding-related complications
Delayed chest closure (%) 2 (6) 5 (17) .25
Postoperative tamponade (%) 1 (3) 4 (13) .25
Re-exploration (%) 5 (17) 14 (48) .004
Total average chest tube output (mL) 810  376 1020  515 .01
Hospital outcomes
Median ICU stay (d) 2 (1–7) 3 (1–15) .44
Prolonged intubation (%) 8 (27) 17 (58) .004
ARDS 2 (6) 5 (17) .25
Pulmonary infection 2 (6) 3 (10) 1
Duration of hospitalization (d) 9  5 10  7 .32
Mortality (%) 2 (6) 2 (6) 1
FFP, Fresh-frozen plasma; ICU, intensive care unit; PRBC, packed red blood cell;
rFVIIa, recombinant activated factor VII; ARDS, acute respiratory distress syndrome.
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Mtechnique. Sudden cardiac arrest developed in this patient
on POD 5 from an episode of aspiration and subsequently
died after failed attempts at resuscitation and a trial of extra-
corporeal membrane oxygenation. At the time of postmor-
tem autopsy, the coronary interposition grafts were patent.
In the control group, the first death occurred from multi-
organ failure on POD 14 in a patient who had undergone
aortic root and ascending aortic replacement. This patient
was re-explored on POD 2 for persistent mediastinal bleed-
ing. The second death in this group occurred on POD 6 in
a similar patient who had persistent postoperative bleeding
requiring re-exploration. The patient eventually expired
from overwhelming sepsis with subsequent cardiac and
renal failure. The patient underwent repair of acute type
A dissection with preoperative tamponade.DISCUSSION
The development of an approach for the management of
inadequate hemostasis due to coagulopathy after aorticTABLE 4. Total thrombosis-related events (n)
rFVIIa n ¼ 29 Control n ¼ 29 Total n ¼ 58
Stroke 1 2 3
TIA 1 1 2
MI 0 1 1
Venous thrombosis 0 0 0
PE 0 0 0
Arterial thrombosis 0 0 0
Total 2 4 6
TIA, Transient ischemic attack;MI,myocardial infarction; PE, pulmonary embolism;
rFVIIa, recombinant activated factor VII.
1202 The Journal of Thoracic and Cardiovascular Sursurgery is essential to have better outcomes.12 Such man-
agement must start at the beginning of the operation to pre-
serve the hemostatic system. Aprotinin has been widely
used to reduce blood loss and blood transfusion require-
ments after thoracic aortic operations13; however, there is
controversy on the use of aprotinin because of its reported
side effects on renal function14 and mortality. In the post-
aprotinin era, there is no consensus for any agent to reduce
bleeding after aortic operations.
Despite its potential for increasing rates of thrombotic
complications, rFVIIa has been shown to be effective in
the management of uncontrolled bleeding after major
operations.6,15-17 In several small randomized trials,
postoperative administration of rFVIIa has been
associated with fewer blood transfusions and lower
mortality rates particularly if limited to therapeutic doses
of 90 mg/kg.18 There currently exist no standardized criteria
for the off-label use of rFVIIa intra- or postoperatively in
cardiovascular surgery. To our knowledge, this study
represents the largest report of intraoperative off-label use
of rFVIIa in patients undergoing cardiothoracic surgery. A
randomized trial also showed the efficacy of intraoperative
use in only 10 patients with an rFVIIa dose of 90 mg/kg.19 In
addition, we have used lower therapeutic doses compared
with those that have been reported.16,20 However, several
other reviews of the literature have demonstrated
a potential association with the complications. In addition,
the recent randomized controlled trial by Gill and
colleagues21 demonstrated a nonsignificant doubling of
serious adverse events and mortality in patients randomly
assigned to receive rFVIIa for the management of excessive
postoperative bleeding after cardiac surgery. Several
recombinant and purified coagulation products are
being studied, and those such as rFVIIa may provide
clinicians specific agents to treat targeted deficiencies;
however, safety is still the most important debate of these
therapies.12
In this study, patients receiving intraoperative rFVIIa had
significantly lower rates of re-exploration for bleeding when
compared with a propensity-matched control group of
patients (17% vs 48%, P ¼ .004). In addition, patients
receiving rFVIIa had significantly lower amounts of chest
tube output, PRBC, and FFP transfusions. It is possible
that the early intraoperative administration of rFVIIa allows
it to exert its effects before the onset of such events and
potentially reduces the dose required for successful man-
agement of coagulopathic bleeding. Some experimental22
and clinical7 studies have shown that hypothermia and aci-
dosis may have a negative impact on the efficacy of rFVIIa.
Several factors, including hemorrhage and transfusion of
blood and blood products, are major contributors to the
development of postoperative hypothermia and acidosis.
Further experimental studies and larger clinical cohorts
are needed to verify the potential benefit of earliergery c May 2012
Goksedef et al Perioperative Managementadministration of low-dose rFVIIa. However, a trend for in-
creased mortality was observed in both low- and medium-
dosing schedules of rFVIIa when this agent was used as
a first-line therapy in a recent randomized controlled trial.21
The incidence of prolonged intubation in the rFVIIa
group was lower than that in the control group. It is
a well-known fact that excessive bleeding after open sur-
gery is an important factor that can prevent early extuba-
tion.23 The lower incidence of prolonged intubation in the
rFVIIa group may also be due to fewer PRBC and FFP
transfusions and the decreased incidence of surgical re-
exploration due tomediastinal bleeding in the rFVIIa group.
However, intraoperative rFVIIa treatment did not affect
the median ICU stay, hospital stay, and in-hospital
mortality.
The safety of rFVIIa has been controversial owing to its
reported risk of increased thrombotic complications.24 Sev-
eral reports suggest that a range of 45 to 90 mg/kg might be
safe and effective when administered postoperatively.25
With our low-dose regimen, we had only 2 patients (7%)
with potential thrombosis-related events. A multinational
registry of rFVIIa use in patients undergoing cardiac sur-
gery suggests a 4% thromboembolic event rate and a 7%
possible or probable adverse event rate at a dose of 92 mg/
kg related to the use of rFVIIa.7 This study included 37%
of aortic cases in which 9% were related to the aortic
arch. In our study, 62% of operations involved the aortic
arch and 77% of patients underwent operations with
DHCA, facts that demonstrate the increased complexity
of the operations. Indeed, we found no significant difference
between the rates of thrombotic complications between
groups. In this study, mortality was not related to throm-
botic complications. The safety of our lower dose may be
attributed to the earlier administration of rFVIIa and second
tier than previously reported.21P
MStudy Limitations
Our study is limited by several factors. This is a retrospec-
tive study and is therefore associated with the known biases
of such studies. Furthermore, there was a significant differ-
ence in baseline prematch variables, thereby mandating the
performance of a propensity-matched analysis as outlined
previously. This method of propensity match itself was lim-
ited by the small number of patients included in the statisti-
cal analysis who received rFVIIa. The findings of this study
cannot be applied to cases involving coronary revasculariza-
tion because of the possible detrimental thrombosis-related
complications of the small size of coronary arteries. Last,
although there was no safety signal detected, this study
has inadequate power to detect a difference in serious
adverse events or complications. We strongly advocate
that future prospective randomized trials be conducted to
verify our findings.The Journal of Thoracic and CarCONCLUSIONS
This study shows that the intraoperative low dose of
rFVIIa is effective in reducing re-exploration for bleeding,
decreasing the need for PRBC and FFP transfusions, and re-
ducing the chest tube output. On the basis of the preliminary
results, we recommend that clinicians consider the intrao-
perative use of low doses of rFVIIa in aortic surgery for
managing inadequate hemostasis that is unresponsive to
routine hemostatic therapy (eg, platelets, FFP, cryoprecipi-
tate). Further prospective randomized studies and larger
cohorts are needed to verify these findings.
The authors thank Maminder Bhatti for the contribution in data
collection.
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